NCT04770961

Brief Summary

The goal of this project is to study whether local anesthetic via the erector spinae plane (ESP) block may be beneficial in minimally invasive mitral valve surgery (MIMVS).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 22, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 25, 2021

Completed
1 month until next milestone

Study Start

First participant enrolled

April 1, 2021

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2022

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2022

Completed
Last Updated

March 3, 2021

Status Verified

March 1, 2021

Enrollment Period

1.2 years

First QC Date

February 22, 2021

Last Update Submit

March 1, 2021

Conditions

Keywords

mitral valve replacementmitral valve repairmitral valve surgeryerector spinae planeminimally invasive surgery

Outcome Measures

Primary Outcomes (1)

  • Total opiate consumption

    Total oral morphine equivalent (milligram) consumption within the first 48 hours of recovery including intra-operative usage, extracted from electronic medical record.

    48 hours.

Secondary Outcomes (8)

  • Pain score

    48 hours

  • Time to extubation.

    Within 30 days from end of operation.

  • Time to first oral intake

    Within 30 days from end of operation.

  • Time to ambulation

    Within 30 days from end of operation.

  • Time to chest tube removal

    Within 30 days from end of operation.

  • +3 more secondary outcomes

Study Arms (2)

Cryoablation

SHAM COMPARATOR

1\. Cryoablation of intercostal nerves + Sham ESP catheter with saline infusion.

Procedure: Erector spinae plane catheter with saline

ESP + Cryoablation

EXPERIMENTAL

2\. Cryoablation of intercostal nerves + ESP catheter with local anesthetic infusion.

Procedure: Erector spinae plane catheter with 0.5% Ropivacaine

Interventions

Ultrasound guided, right sided, ESP catheter inserted at the level of T5. 20 cc injection of 0.5% Ropivacaine is injected at the time of catheter placement. Postoperatively, a programmed intermittent bolus infusion of 0.2% Ropivacaine will be delivered via the ESP catheter.

ESP + Cryoablation

Ultrasound guided, right sided, ESP catheter inserted at the level of T5. 20 cc injection of saline is injected at the time of catheter placement. Postoperatively, a programmed intermittent bolus infusion of saline will be delivered via the ESP catheter.

Also known as: Sham
Cryoablation

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Elective mitral valve repair or replacement
  • Planned minimally invasive approach

You may not qualify if:

  • Non-English speaking
  • Emergency surgery
  • Planned or unplanned sternotomy
  • Previous history of sternotomy and cardiac surgery
  • Allergy to ropivacaine
  • Patients taking more than 60 OMEs per day
  • Patients with coagulopathy or taking anticoagulant with laboratory findings contraindicated for ESP catheter

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of California, San Francisco

San Francisco, California, 94143, United States

Location

MeSH Terms

Conditions

Mitral Valve InsufficiencyMitral Valve Prolapse

Interventions

RopivacaineSodium Chloridesalicylhydroxamic acid

Condition Hierarchy (Ancestors)

Heart Valve DiseasesHeart DiseasesCardiovascular DiseasesHeart Valve Prolapse

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Wilson Cui, MD, PhD

    University of California, San Francisco

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Wilson Cui, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 22, 2021

First Posted

February 25, 2021

Study Start

April 1, 2021

Primary Completion

June 30, 2022

Study Completion

August 30, 2022

Last Updated

March 3, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will not share

Locations